The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
MaaT Pharma Enters Exclusive Commercialization Partnership With Clinigen for Xervyteg® Targeting Acute Graft-versus-Host Disease in Europe
Jul 03, 2025•12 months ago
Contract Type
partnership
LyonBiotechnologyHealth CareTherapeutics
Description
MaaT Pharma has signed an exclusive long-term licensing and distribution agreement with Clinigen for its treatment Xervyteg® aimed at acute Graft-versus-Host Disease. The agreement includes an upfront payment and potential milestones totaling €28.5 million, plus royalties on net sales.
Company Information
Company
MaaT Pharma
Location
Lyon, Auvergne Rhône Alpes, France
About
MaaT Pharma is a clinical-stage biotechnology company, leading in the development of Microbiome Ecosystem TherapiesTM (MET)1 to improve the survival of patients with cancer. The company is committed to restoring the microbiome/host symbiosis of patients with cancer and graft versus host disease (GvHD). MaaT Pharma has launched a Phase 3 clinical trial in Europe for patients with acute GvHD, after demonstrating the concept in a Phase 2 clinical trial.
LyonBiotechnologyHealth CareTherapeutics